Group 1 - Core viewpoint: Yinos Biotech Co., Ltd. has seen a stock price increase of 5.66%, reaching 46.65 CNY per share, with a total market capitalization of 6.577 billion CNY as of January 5 [1] - Company overview: Yinos Biotech, established on May 12, 2010, is located in the China (Shanghai) Pilot Free Trade Zone and specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1] - Revenue breakdown: The company's revenue composition includes 96.31% from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] Group 2 - Major shareholder: Huatai-PineBridge Fund's Huatai Medical Health Mixed Fund (470006) has entered the top ten circulating shareholders of Yinos, holding 1.1215 million shares, which is 1.24% of the circulating shares [2] - Fund performance: The Huatai Medical Health Mixed Fund has achieved a year-to-date return of 22.9%, ranking 4015 out of 8155 in its category, with a total fund size of 2.486 billion CNY [2] - Fund manager: The fund manager, Zheng Lei, has been in position for 11 years and 23 days, overseeing a total asset size of 8.093 billion CNY, with the best fund return during his tenure being 53.42% [3]
益诺思股价涨5.66%，汇添富基金旗下1只基金位居十大流通股东，持有112.15万股浮盈赚取280.38万元